Internal medicine

Clinical endpoint

Taxane

Prostate cancer

Cancer

Urology

Oncology

Prostate

Chemotherapy

Progressive disease

Response Evaluation Criteria in Solid Tumors

Breast cancer

Clinical trial

Medicine

The Lancet Oncology

Our findings show that radionuclide treatment with [177Lu]-PSMA-617 has high response rates, low toxic effects, and reduction of pain in men with metastatic castration-resistant prostate cancer who have progressed after conventional treatments. This evidence supports the need for randomised controlled trials to further assess efficacy compared with current standards of care.

[ 177 Lu]-PSMA-617 radionuclide treatment in patients with metastatic castration-resistant prostate cancer (LuPSMA trial): a single-centre, single-arm, phase 2 study